menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Santhera Reaches Pricing Deal In Germany For AGAMREE In DMD

    GLOBENEWSWIRE

    Santhera Gains NICE Guidance For Agamree In DMD

    GLOBENEWSWIRE

    Santhera Updates Royalty Deal For AGAMREE® And Idorsia Warrants

    GLOBENEWSWIRE

    Santhera Gains AGAMREE® Approval for Duchenne in NHS Scotland

    GLOBENEWSWIRE

    Santhera Enter into Supply & Distribution for Agamree with Clinigen

    GLOBENEWSWIRE

    Santhera Announces AGAMREE® Approval for Duchenne in Hong Kong

    GLOBENEWSWIRE

    Santhera Receives NMPA Approval for Agamree in DMD

    GLOBENEWSWIRE

    Santhera Gets NICE for AGAMREE® in Duchenne Muscular Dystrophy

    GLOBENEWSWIRE

    Santhera Signs Supply Deal for Vamorolone with Ali Al Suwaidi

    GLOBENEWSWIRE

    Santhera Reports Positive Results From LIONHEART Study

    GLOBENEWSWIRE

    Swissmedic Accepts Santhera`s AGAMREE Marketing Application

    GLOBENEWSWIRE

    Santhera Announces H1 2024 Results And Corporate Update

    GLOBENEWSWIRE

    Santhera Enters Distribution Agreement With GENESIS Pharma

    GLOBENEWSWIRE

    Catalyst Pharma Licenses AGAMREE To Kye Pharma For Canada Market

    GLOBENEWSWIRE

    Pfizer`s Setback In DMD Trial Clears Path For Sarepta And Others | DelveInsight

    PR NEWSWIRE

    Santhera announces Early Access Program by partner Sperogenix for DMD treatment

    PHARMAFILE

    Santhera Launches China Early Access For AGAMREE Via Sperogenix

    GLOBENEWSWIRE

    Santhera Announces NDA for vamorolone in DMS Accepted and GPR by China

    GLOBENEWSWIRE

    Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States

    GLOBENEWSWIRE

    Catalyst Announces Publication of Santhera`s VISION-DMD Vamorolone Study Results

    GLOBENEWSWIRE

    Santhera Announces Publication of Efficacy and Tolerability Data with Vamorolone

    GLOBENEWSWIRE

    Santhera Launches AGAMREE in Germany as First Market for DMD

    GLOBENEWSWIRE

    Santhera Receives Approval for AGAMREE as a Treatment for DMD

    GLOBENEWSWIRE

    Santhera’s Agamree gains EU approval for Duchenne muscular dystrophy

    GLOBENEWSWIRE

    Santhera`s drug gets US FDA nod for rare muscular dystrophy

    GLOBENEWSWIRE

    Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE

    GLOBENEWSWIRE

    Catalyst Pharma Acquires Exclusive North American License For Vamorolone

    GLOBENEWSWIRE

    Santhera Announces Closing of Agreement with Catalyst for Vamorolone

    GLOBENEWSWIRE

    Catalyst to License North American Rights to Vamorolone for DMD from Santhera

    GLOBENEWSWIRE

    Catalyst licenses Santhera Pharma’s vamorolone in North America

    PHARMACEUTICAL TECHNOLOGY

    Santhera Grants Exclusive North America License for Vamorolone to Catalyst

    GLOBENEWSWIRE

    Santhera and ReveraGen Announce FDA Acceptance of NDA for Vamorolone

    GLOBENEWSWIRE

    Santhera seeks speedy FDA review of Duchenne drug vamorolone

    PHARMAPHORUM

    Santhera Submits Marketing Authorization Application to the EMAyfor Vamorolone

    GLOBENEWSWIRE

    Santhera submits marketing authorisation application for vamorolone

    PHARMATIMES

    JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone

    GLOBENEWSWIRE

    Santhera and ReveraGen Announce 1st Participant Dosed in FDA-funded PII study

    GLOBENEWSWIRE

    Santhera Updates on Ongoing NDA Submission for Vamorolone

    GLOBENEWSWIRE

    Santhera, ReveraGen to Present Efficacy & Safety Data with Vamorolone at MDA

    GLOBENEWSWIRE

    Santhera Enters into Excl License Agreement with Sperogenix for Vamorolone

    GLOBENEWSWIRE

    Santhera, ReveraGen announce positive topline results with vamorolone

    PHARMABIZ

    Santhera & ReveraGen Announce +veTopline Results with Vamorolone

    GLOBENEWSWIRE

    Santhera und ReveraGen geben erfolgreiches FDA-Pre-NDA-Meeting für Vamorolone

    GLOBENEWSWIRE

    Santhera &ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone

    GLOBENEWSWIRE

    Santhera Announces Publication on Molecular Distinctions of Vamorolone

    GLOBENEWSWIRE

    Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone

    GLOBENEWSWIRE

    Santhera Announces Completion of ReveraGen’s Long-Term Study with Vamorolone

    GLOBENEWSWIRE

    ReveraGen`s Anti-Inflammatory Demonstrates Positive Results

    BIOSPACE

    ReveraGen reports positive data for vamorolone in DMD

    CLINICALTRIALSARENA

    Santhera`s Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there`s a lot left to prove

    ENDPTS

    Idorsia sheds surplus DMD therapy to Santhera

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.